Abbott Laboratories (ABT)
131.65
+0.27 (0.20%)
NYSE · Last Trade: Oct 14th, 11:38 AM EDT
Healthcare product and device company Abbott Laboratories (NYSE:ABT)
will be reporting earnings this Wednesday morning. Here’s what investors should know.
Via StockStory · October 13, 2025
New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early 2025, following pivotal statements from President Donald Trump regarding his administration's tariff policies. These sudden rallies underscore the profound sensitivity
Via MarketMinute · October 13, 2025
Via Benzinga · October 13, 2025
Retail investors are preparing for the kick-off of the Q3 earnings season, with big banks and other top stocks reporting this week.
Via Benzinga · October 13, 2025
Via Benzinga · October 8, 2025
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via StockStory · October 8, 2025
Via Benzinga · October 7, 2025
The time is right for buying more of these great dividend stocks.
Via The Motley Fool · October 7, 2025
In a monumental stride towards democratizing global healthcare, researchers at the University of Liverpool have announced the development of a pioneering low-cost, handheld, AI-powered blood test designed for the early detection of Alzheimer's disease biomarkers. This groundbreaking innovation, widely reported between October 1st and 6th, 2025, promises to revolutionize how Alzheimer's is diagnosed, making testing [...]
Via TokenRing AI · October 6, 2025
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Via MarketMinute · October 2, 2025
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Via StockStory · October 2, 2025
This fund makes it easy to invest in the top dividend stocks.
Via The Motley Fool · September 29, 2025
Mumbai, India – September 27, 2025 – Abbott India Limited (NSE: ABBOTINDIA), a prominent player in the Indian pharmaceutical sector, is exhibiting a robust financial trajectory and a promising valuation outlook. Propelled by strong Q1 FY2025-2026 results and strategic market maneuvers, the company continues to solidify its position in the rapidly expanding
Via MarketMinute · September 27, 2025
Discover Abbott Laboratories (ABT), a top Caviar Cruise screen pick. This healthcare leader excels in profitability, financial health, and cash flow, making it a strong long-term quality investment.
Via Chartmill · September 27, 2025
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Via StockStory · September 25, 2025
Abbott Laboratories (ABT) is a technical breakout candidate, showing a strong uptrend and a perfect consolidation setup, suggesting a potential upward move.
Via Chartmill · September 24, 2025
The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes.
Via Benzinga · September 23, 2025
These businesses may be "boring," but that's a good thing in today's market.
Via The Motley Fool · September 21, 2025
These dividend powerhouses compound wealth through decades of consecutive increases and sustainable payout ratios.
Via The Motley Fool · September 19, 2025
The financial markets are currently a tempestuous sea, marked by a perplexing interplay of underlying strength and overt volatility, largely driven by the powerful forces of investor psychology. As of September 2025, a fascinating dichotomy exists: while some indicators point to compressed volatility, hinting at a degree of investor complacency,
Via MarketMinute · September 22, 2025
Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from Abbott's Libre 3.
Via Benzinga · September 18, 2025
As autumn leaves begin to fall, a familiar chill often descends upon the financial markets, not just in temperature but in investor sentiment. September has historically earned a notorious reputation among traders and analysts as the weakest month for equities, a phenomenon widely dubbed the "September Effect." This recurring statistical
Via MarketMinute · September 15, 2025
The attraction of these dividend stocks isn't limited to their dividends.
Via The Motley Fool · September 13, 2025